Trial Profile
A Multi-center, Randomized, Double-blind, Placebo-controlled Trial to Evaluate the Neurological Effects of EryDex in Subjects With Ataxia Telangiectasia (NEAT)
Status:
Recruiting
Phase of Trial:
Phase III
Latest Information Update: 03 May 2025
Price :
$35
*
At a glance
- Drugs Dexamethasone (Primary)
- Indications Ataxia telangiectasia
- Focus Registrational; Therapeutic Use
- Acronyms the NEAT Trial
- Sponsors EryDel
Most Recent Events
- 24 Mar 2025 According to a Quince Therapeutics media release, the company announced enrollment of 61 participants to date in this trial, the trial exceeds 50% enrollment with new study site activations expected to accelerate screenings and randomization.
- 24 Mar 2025 According to a Quince Therapeutics media release, the company expect to report topline results in the fourth quarter of 2025 with NDA submission to the FDA and a Marketing Authorization Application (MAA) submission to the European Medicines Agency (EMA) in 2026, assuming positive study results.
- 07 Feb 2025 According to a Quince Therapeutics media release, the company announced enrollement of 46 participants to date in this trial, Phase 3 NEAT clinical trial nearing 50% enrollment;